Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Addex TherapeuticsFRA:APE1 +7.14%7 PS Ratio is 154.41 as of Jul. 14, 2026, which is 1157% above its 10-year median of 12.28. GuruFocus rates FRA:APE1 with a GF Score™ of 7/100 and a GF Value™ of €1.22. The stock has 6 warning signs investors should review. Among 930 Biotechnology companies, Addex Therapeutics ranks worse than 107526.77% on this metric.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Addex Therapeutics's share price is €5.25.
Addex Therapeutics's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 was €0.03. Hence, Addex Therapeutics's PS Ratio for today is 154.41.
The historical rank and industry rank for Addex Therapeutics's PS Ratio or its related term are showing as below:
During the past 13 years, Addex Therapeutics's highest PS Ratio was 67.80. The lowest was 1.83. And the median was 12.28.
FRA:APE1's PS Ratio is not ranked *
in the Biotechnology industry.
Industry Median: 9.405 * Ranked among companies with meaningful PS Ratio only.
During the past 13 years, Addex Therapeutics's highest 3-Year average Revenue per Share Growth Rate was 51.00% per year. The lowest was -63.90% per year. And the median was -45.40% per year.
Back to Basics: PS Ratio
Addex Therapeutics (FRA:APE1) PS Ratio Explanation
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
Addex Therapeutics PS Ratio Related Terms
Addex Therapeutics PS Ratio Historical Data
* Premium members only.
The historical data trend for Addex Therapeutics's PS Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Addex Therapeutics's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Addex Therapeutics PS Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Addex Therapeutics's PS Ratio distribution charts can be found below:
* The bar in red indicates where Addex Therapeutics's PS Ratio falls into.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
Addex Therapeutics's Share Price of today is €5.25. Addex Therapeutics's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.03.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Addex Therapeutics (FRA:APE1) has a PS Ratio of 154.41 as of Jul. 14, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Addex Therapeutics and its competitors. This is 1157% above median its historical median of 12.28. Over the past decade, Addex Therapeutics' PS Ratio has ranged from 1.83 to 67.80. According to the industry distribution chart, Addex Therapeutics ranks #999999 out of 930 companies in the Biotechnology industry.
Is Addex Therapeutics' PS Ratio too high?
Addex Therapeutics' current PS Ratio of 154.41 is 1157% above median its 10-year median of 12.28. Over the past 10 years, this metric has ranged from a low of 1.83 to a high of 67.80. The Biotechnology industry median PS Ratio is 9.41. Addex Therapeutics' value of 154.41 is 1541.8% above this industry median. Based on the distribution chart, Addex Therapeutics ranks #999999 out of 930 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Addex Therapeutics has a GF Score™ of 7/100, reflecting its overall financial health beyond just this single metric.
How does Addex Therapeutics' PS Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Addex Therapeutics ranks #999999 out of 930 companies for PS Ratio. This places Addex Therapeutics in the lower half of its industry. The industry median PS Ratio is 9.41. Addex Therapeutics' value of 154.41 is 1541.8% above this benchmark. Historically, Addex Therapeutics' own PS Ratio has ranged from 1.83 to 67.80 over the past decade. While the company's 10-year median is 12.28 vs. the industry median of 9.41, Addex Therapeutics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Biotechnology company?
The median PS Ratio among Biotechnology companies is 9.41, based on 930 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Addex Therapeutics's current PS Ratio of 154.41 is 1541.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Addex Therapeutics and its competitors. For the Biotechnology industry, the median PS Ratio is 9.41 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Addex Therapeutics's current PS Ratio is 154.41, which is 1157% above median its own 10-year median of 12.28. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Addex Therapeutics stock overvalued right now?
Addex Therapeutics (FRA:APE1) has a current PS Ratio of 154.41. The stock's GF Value™ is €1.22, compared to a current price of €5.25 — trading 330.3% above its estimated fair value. The current PS Ratio is 154.41, which is 1157% above median its 10-year median of 12.28 and 1541.8% above the Biotechnology industry median of 9.41. Addex Therapeutics' overall GF Score™ is 7/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For Addex Therapeutics (FRA:APE1), the current PS Ratio is 154.41 as of Jul. 14, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Addex Therapeutics (FRA:APE1) Overvalued in 2026?
Based on GuruFocus' analysis, Addex Therapeutics stock appears to be overvalued.
The current stock price of €5.25 is trading 330.3% above its estimated GF Value™ of €1.22.
Key valuation signals for FRA:APE1:
PS Ratio: 154.41 (1157% above median its 10-year median of 12.28)
GF Value™: €1.22 vs. price of €5.25 (330.3% above fair value)
Industry Position: 1541.8% above the Biotechnology median (#999999 of 930)
No single metric tells the full story. See the FRA:APE1 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Addex Therapeutics Ltd is a clinical-stage biopharmaceutical company. The company is focused on the development and commercialization of an emerging class of novel orally available small-molecule drugs known as allosteric modulators. The company's geographical area of operations includes Switzerland and Europe. The Company operates in one segment, which is the discovery, development, and commercialization of small-molecule pharmaceutical products.
7GF Score
Get the complete analysis for FRA:APE1
PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:APE1 has been successfully added to your 
